The present application generally relates to systems and methods for treating acute heart failure through augmentation of parasympathetic and sympathetic cardiovascular control.
Acute heart failure syndromes (AHFS) are serious conditions resulting in millions of hospitalizations each year. Well documented in the literature are causal links between declining renal function or myocardial injury during AHFS hospitalization and poor prognosis. Heart failure resulting from myocardial ischemic insult or tachycardia precipitates complex alterations in autonomic tone, neurohormonal activation, and the inflammatory metabolic state. These changes in autonomic tone are typically manifested by increased heart rate and a reduction in heart rate variability. In the setting of an acute exacerbation of heart failure, the dramatically elevated heart rate is frequently accompanied by hypotension. The critical role of treating the autonomic nervous system dysfunction observed in HF has long been recognized (with inotropic agents and beta-blockers). Recently, specific neuromodulation of the parasympathetic cardiac nerve inputs has shown significant therapeutic benefit. Cleland J. G., Bristow M. R., Erdmann E, Remme W. J., Swedberg K, Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J 1996;17:1629-39; De Ferrari G. M., Crijns H. J., Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011;32:847-55.
However, in the case of AHFS associated with congestive symptoms and reduced blood pressure (BP), the negative inotropic effects of lone parasympathetic intervention or beta-blockade can severely limit their utility. In the face of hypotension, sympathetic tone must be maintained in order to assure adequate left ventricular (LV) contractility. Anand I. S., Fisher L. D., Chiang Y. T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83. Animal studies have demonstrated positive inotropic effects (increased LV pressure and cardiac output without change in systemic vascular resistance) when selectively stimulating certain cardiac efferent sympathetic nerves. Zarse M, Plisiene J, Mischke K, et al. Selective increase of cardiac neuronal sympathetic tone: a catheter-based access to modulate left ventricular contractility. J Am Coll Cardiol 2005;46:1354-9; Meyer C, Rana O. R., Saygili E, et al. Augmentation of left ventricular contractility by cardiac sympathetic neural stimulation. Circulation 2010;121:1286-94.
The autonomic nervous system includes the parasympathetic nervous system and the sympathetic nervous system. The parasympathetic and sympathetic nervous system have somewhat opposing effects on the cardiovascular system. One function of the parasympathetic nervous system is to slow the heart through action of the vagus nerve. On the other hand, the sympathetic nervous system is associated with increasing the heart rate and increasing the contractility of the heart. The disclosed system and method augment balance between the sympathetic and parasympathetic systems in AHFS patents so as to lower heart rate and increase heart contractility.
A neuromodulation system for treating AHFS provides therapeutic elements for simultaneous and/or alternating modulation of parasympathetic and sympathetic fibers to improve autonomic balance in the heart. In preferred embodiments, the therapeutic elements are positioned on one or more catheters positioned in the vasculature of the patient and are energized to modulate nerve fibers positioned outside the vascular walls. Modulation may be carried out to activate and/or inhibit activation of target nerve fibers. In the disclosed system, the therapeutic elements are described as electrodes, although it is contemplated that other forms of therapeutic elements (including, but not limited to, ultrasound, thermal, or optical elements) may instead be used.
The parasympathetic and sympathetic fibers may be modulated from the same therapeutic element or element array, or from difference elements or element arrays. Elements used to modulate sympathetic fibers may be positioned in the same blood vessels as those used for the parasympathetic fibers, or they may be in different blood vessels. The blood vessel and the target position of the therapeutic elements within a chosen vessel is selected based on the vessel's anatomic location relative to the target fiber so as to position the therapeutic element in close proximity to the target fiber while minimize collateral effects. For example, as reported in the literature, in the canine model, right sympathetic fibers modulating left ventricular contractility converge at the common pulmonary artery and course in the pulmonary artery nerves. Left sympathetic fibers modulating ventricular contractility (inotropy) are found near the common pulmonary artery, pulmonary artery nerves, and ventral lateral cardiac nerve. In contrast, sympathetic fibers controlling chronotropic and dromotropic functions are found between the superior vena cava (SVC) and aorta, between the common pulmonary artery and the proximal right pulmonary artery, between the left superior pulmonary vein and the right pulmonary artery, and elsewhere. J. L. Ardell et al, Differential sympathetic regulation of automatic, conductile, and contractile tissue in dog heart. The anatomy thus allows a therapeutic element to be positioned to selectively stimulate sympathetic fibers controlling ventricular inotropy to increase contractility, while avoiding chronotropic/dromotropic effects so as not to trigger tachycardia.
In human use, modulation of sympathetic fibers may be achieved using a therapeutic element positioned within the pulmonary artery so as to stimulate sympathetic fibers to increase inotropy. Moreover, therapeutic elements could additionally or alternatively be employed to stimulate parasympathetic fibers that lower heart rate. Such fibers may also be activated using intravascular electrodes located in the pulmonary arteries, although in other embodiments vagal or other parasympathetic fibers are modulated using a therapeutic element in the superior vena cava or the internal jugular vein, preferably on the right side.
In some embodiments, combined or alternating modulation of the parasympathetic and sympathetic fibers may be employed to optimize the opposing effects of parasympathetic and sympathetic modulation on heart rate—such that modulation optimizes the ability of the parasympathetic system to drive the heart rate and the sympathetic system to “apply the brakes” to slow the heart when necessary. Sensed or derived hemodynamic parameters may be used by the system to select and implement stimulation parameters, algorithms and/or to identify the therapeutic element(s) to be activated at a given time. Suitable sensed or derived hemodynamic parameters include pulmonary capillary wedge pressure (PCWP), cardiac index, derivations of vascular resistance, heart rate, blood pressure (arterial). Other parameters may include central venous pressure, CO/CI, and cardiac filling pressures.
Feedback to stimulation configuration manager 11 of pulse generator/stimulator 12 is provided by one or more diagnostic sensors, including feedback from a Swan-Ganz catheter 18 for determining PCWP as well as other sensors used in the detection/derivation of the parameters disclosed above or indicated in
An external monitor 21 allows the user to observe sensed or derived parameters. User instructions are input to the stimulation configure manager using user interface 23.
In a preferred embodiment, the system is programmed to integrate hemodynamic and related data in real-time and to control parasympathetic and sympathetic modulation using the therapeutic elements in a manner that maintains favorable hemodynamics. A treatment regimen is preferably automatically selected or calculated by the microprocessor driven system based on the patient's clinical picture. For example, vascular failure (diastolic) might require parasympathetic stimulation to decrease vascular resistance and increase cardiac cycle length, while therapy for cardiogenic shock might require increased cardiac output. In many cases, maximal benefit will be achieved through both sympathetic and parasympathetic modulation either simultaneously or at different times. The therapy could then be titrated as discussed above to optimize sympathetic/parasympathetic balance as the autonomic system does on its own when in the healthy physiologic state.
In preferred embodiments, the first and second therapeutic elements are electrodes or electrode arrays, although it is contemplated that other forms of therapeutic elements (including, but not limited to, ultrasound, thermal, or optical elements) may instead be used. The therapeutic elements are positioned on flexible catheters.
The catheters include features expandable within the vasculature for biasing the electrodes into contact with the interior surfaces of the blood vessels so as to optimize conduction of neuromodulation energy from the electrodes to the target nerve fibers and to anchor the catheter and electrodes at the desired position for the duration of the treatment. In the embodiments shown, the electrodes on the SVC catheter 14 and the pulmonary artery catheter 16 are carried by electrode carrying members 50a, 50b. Each electrode carrying member has a compressed, streamlined position for pre-deployment passage of the catheter and electrode carrying member through the vasculature during advancement of the electrodes towards the target electrode site. Each electrode carrying member is expandable to an expanded position in which at least a portion of the electrode carrying member is radially deployed towards the interior wall of the blood vessel so as to bias the electrode(s) into contact with the vessel wall.
The drawings show electrode carrying members constructed of spline elements 52a, 52b formed of resilient material such as nitinol, stainless steel, resilient polymer or another resilient material. The spine elements are moveable to a deployed position in a manner known in the art, to cause the spine elements to bow or extend outwardly when the electrode carrying member is moved to the expanded position. Electrodes 53a, 53b are positioned on the spline elements. The electrodes can be the splines themselves, or conductive regions of the splines where the remaining portions of the splines covered or coated with insulative material. Alternatively, electrodes may be attached to the splines, or printed or plated onto the splines.
In the catheter system illustrated in the drawings, the catheters are designed to be percutaneously introduced (e.g. using access through the femoral vein, subclavian, or internal jugular vein). As shown in
Pulmonary artery catheter 16 extends through the lumen 42 of the SVC catheter. If pull-wire deployment is used to move the splines of the pulmonary artery catheter to the outwardly-bowed position, pull wires 38 extend through lumens in the walls of the PA catheter between the spline structure and an actuator disposed at the proximal end of the catheter, which remains outside the body during use. Conductors 40 extending through the PA catheter are electrically coupled to the electrodes 53b (
The proximal ends of the three telescoping catheters are illustrated in
Positioning of the system 10 will next be described with reference to
Next, the pulmonary artery catheter 16 is advanced over the Swan-Ganz, with the lumen of the PA catheter disposed over the Swan-Ganz, until its electrode carrying member 50b is within the pulmonary artery. The electrode carrying member is expanded within the pulmonary artery (either before or after the SVC catheter is introduced into the SVC), placing the electrodes 53b into contact with the walls of the pulmonary artery.
The SVC catheter 14 is positioned by passing the SVC catheter over the PA catheter and advancing the SVC catheter until its electrode carrying member 50a is within the SVC.
The electrode carrying member is expanded, placing the electrodes 53a into contact with the walls of the SVC.
In a modified method, the PA catheter is advanced into the pulmonary artery using methods besides passage over a Swan-Ganz. For example, the PA catheter could be advanced over another type of catheter or a guidewire introduced into the pulmonary artery.
Once positioned in the vasculature, mapping procedures may be carried out as known in the art to identify the optimal positions of the therapeutic elements within the vasculature. For example, mapping may be used to determine (a) which spline on a given catheter is best positioned to capture the nerve fibers (e.g. the vagus nerve for the SVC catheter and parasympathetic cardiac nerves for the PA catheter) for which neuromodulation is intended, and/or (b) which electrodes on a given spline are in the best position to capture the target nerve fibers, and/or (c) whether the electrode carrying member should be collapsed and repositioned for additional mapping at a second site within the blood vessel. The expandable nature of the distal ends of the SVC and PA catheters temporarily maintains the position of the therapeutic elements at the target sites during the period of time that the patient is undergoing treatment. It bears mention that the spline arrangements are but one example of an expandable electrode carrying member which may be used in the disclosed system. In other embodiments, the telescoping catheters might utilize expandable anchor arrangements such as those of the type disclosed in co-pending U.S. application Ser. No. 13/281,399, entitled Intravascular Electrodes and Anchoring Devices, filed 25 Oct. 2011, which is incorporated herein by reference. Various other forms of temporary anchors may also be used for this purpose, including many that are known in the art for use in cardiac mapping and/or stimulation as well as those used for transvascular nerve stimulation.
The application is a continuation of PCT/US12/35712, filed 28 Apr. 2012, which claims the benefit of U.S. Provisional Application No. 61/480,305, filed 28 Apr. 2011, the entirety of each of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4240433 | Bordow | Dec 1980 | A |
5154172 | Terry, Jr. | Oct 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5269303 | Wernicke | Dec 1993 | A |
5304206 | Baker, Jr. | Apr 1994 | A |
5531779 | Dahl | Jul 1996 | A |
5651378 | Matheny | Jul 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. | Jan 1998 | A |
5913876 | Taylor | Jun 1999 | A |
5928272 | Adkins | Jul 1999 | A |
5954761 | Machek | Sep 1999 | A |
6181966 | Nigam | Jan 2001 | B1 |
6292695 | Webster, Jr. | Sep 2001 | B1 |
6429217 | Pkas | Aug 2002 | B1 |
6445953 | Bulkes | Sep 2002 | B1 |
6449507 | Hill | Sep 2002 | B1 |
6473644 | Terry, Jr. | Oct 2002 | B1 |
6479523 | Pkas | Nov 2002 | B1 |
6522926 | Kieval | Feb 2003 | B1 |
6529779 | Sutton | Mar 2003 | B1 |
6542774 | Hill | Apr 2003 | B2 |
6564096 | Mest | May 2003 | B2 |
6616624 | Kieval | Sep 2003 | B1 |
6622041 | Terry, Jr. | Sep 2003 | B2 |
6656960 | Pkas | Dec 2003 | B2 |
6690971 | Schauerte | Feb 2004 | B2 |
6697676 | Dahl | Feb 2004 | B2 |
6721603 | Zabara | Apr 2004 | B2 |
6748272 | Carlson | Jun 2004 | B2 |
6778854 | Pkas | Aug 2004 | B2 |
RE38705 | Hill | Feb 2005 | E |
6850801 | Kievel | Feb 2005 | B2 |
6885888 | Rezai | Apr 2005 | B2 |
6907285 | Denker | Jun 2005 | B2 |
6912419 | Hill | Jun 2005 | B2 |
6934583 | Weinberg | Aug 2005 | B2 |
6937896 | Kroll | Aug 2005 | B1 |
6978174 | Gelfand | Dec 2005 | B2 |
6985774 | Kieval | Jan 2006 | B2 |
7069070 | Carlson | Jun 2006 | B2 |
7072720 | Pkas | Jul 2006 | B2 |
7110828 | Kolberg | Sep 2006 | B2 |
7123959 | Cates | Oct 2006 | B2 |
7123961 | Kroll | Oct 2006 | B1 |
7139607 | Shelchuk | Nov 2006 | B1 |
7142917 | Fukui | Nov 2006 | B2 |
7149574 | Yun | Dec 2006 | B2 |
7162303 | Levin | Jan 2007 | B2 |
7181288 | Rezai | Feb 2007 | B1 |
7184829 | Hill | Feb 2007 | B2 |
7194313 | Libbus | Mar 2007 | B2 |
7225019 | Jahns | May 2007 | B2 |
7231260 | Wallace | Jun 2007 | B2 |
7269457 | Shafer | Sep 2007 | B2 |
7277761 | Shelchuk | Oct 2007 | B2 |
7299091 | Barrett | Nov 2007 | B2 |
7310552 | Pkas | Dec 2007 | B2 |
7330765 | Haldeman | Feb 2008 | B2 |
7336997 | Fukui | Feb 2008 | B2 |
7340299 | Pkas | Mar 2008 | B2 |
7363076 | Yun | Apr 2008 | B2 |
7386345 | Pastore | Jun 2008 | B2 |
7455753 | Roth | Nov 2008 | B2 |
7477945 | Rezai | Jan 2009 | B2 |
7485104 | Kieval | Feb 2009 | B2 |
7486991 | Libbus | Feb 2009 | B2 |
7499744 | Carlson | Mar 2009 | B2 |
7499748 | Moffitt | Mar 2009 | B2 |
7509166 | Libbus | Mar 2009 | B2 |
7519421 | Denker | Apr 2009 | B2 |
7519424 | Dennis | Apr 2009 | B2 |
7532938 | Machado | May 2009 | B2 |
7555341 | Moffitt | Jun 2009 | B2 |
7555351 | Zhang | Jun 2009 | B2 |
7561923 | Libbus | Jul 2009 | B2 |
7572226 | Scheiner | Aug 2009 | B2 |
7596413 | Libbus | Sep 2009 | B2 |
7617003 | Caparso | Nov 2009 | B2 |
7617005 | Demarais | Nov 2009 | B2 |
7620451 | Demarais | Nov 2009 | B2 |
7634317 | Ben-David | Dec 2009 | B2 |
7643875 | Heil, Jr. | Jan 2010 | B2 |
7647114 | Libbus | Jan 2010 | B2 |
7647115 | Levin | Jan 2010 | B2 |
7653438 | Deem | Jan 2010 | B2 |
7676275 | Farazi | Mar 2010 | B1 |
7717948 | Demarais | May 2010 | B2 |
7747323 | Libbus | Jun 2010 | B2 |
7756583 | Demarais | Jul 2010 | B2 |
7765000 | Zhang | Jul 2010 | B2 |
7769446 | Moffitt | Aug 2010 | B2 |
7769470 | Rezai | Aug 2010 | B1 |
7778704 | Rezai | Aug 2010 | B2 |
7778711 | Ben-David | Aug 2010 | B2 |
7783362 | Whitehurst | Aug 2010 | B2 |
7801627 | Haldeman | Sep 2010 | B2 |
7809447 | Dreier | Oct 2010 | B2 |
7813812 | Kieval | Oct 2010 | B2 |
7833164 | Scheiner | Nov 2010 | B2 |
7840278 | Pkas | Nov 2010 | B1 |
7853333 | Demarais | Dec 2010 | B2 |
7865237 | Machado | Jan 2011 | B2 |
7865249 | Reddy | Jan 2011 | B2 |
7869881 | Libbus | Jan 2011 | B2 |
7873417 | Demarais | Jan 2011 | B2 |
7877146 | Rezai | Jan 2011 | B2 |
7881788 | Fukui | Feb 2011 | B2 |
7885711 | Ben-Ezra | Feb 2011 | B2 |
7890187 | Hochareon | Feb 2011 | B2 |
7890188 | Zhang | Feb 2011 | B2 |
7904175 | Scott | Mar 2011 | B2 |
7917230 | Bly | Mar 2011 | B2 |
7937143 | Demarais | May 2011 | B2 |
7949409 | Bly | May 2011 | B2 |
7962214 | Byerman | Jun 2011 | B2 |
8024050 | Libbus | Sep 2011 | B2 |
8032215 | Libbus | Oct 2011 | B2 |
8046075 | Rezai | Oct 2011 | B2 |
8126560 | Scheiner | Feb 2012 | B2 |
8412350 | Bly | Apr 2013 | B2 |
8532793 | Morris et al. | Sep 2013 | B2 |
20030004549 | Hill | Jan 2003 | A1 |
20030229380 | Adams | Dec 2003 | A1 |
20040019364 | Kieval | Jan 2004 | A1 |
20040176672 | Silver | Sep 2004 | A1 |
20050096710 | Kieval | May 2005 | A1 |
20050149156 | Libbus | Jul 2005 | A1 |
20050251238 | Wallace | Nov 2005 | A1 |
20050251239 | Wallace | Nov 2005 | A1 |
20050288730 | Deem et al. | Dec 2005 | A1 |
20060079945 | Libbus | Apr 2006 | A1 |
20060229677 | Moffit | Oct 2006 | A1 |
20060235474 | Demarais et al. | Oct 2006 | A1 |
20060253161 | Libbus et al. | Nov 2006 | A1 |
20070129763 | Cates | Jun 2007 | A1 |
20070142879 | Greenberg | Jun 2007 | A1 |
20070191904 | Libbus | Aug 2007 | A1 |
20070282412 | Soltis | Dec 2007 | A1 |
20070282414 | Soltis | Dec 2007 | A1 |
20070288076 | Bulkes | Dec 2007 | A1 |
20070293925 | Zarembo | Dec 2007 | A1 |
20080009917 | Rossing | Jan 2008 | A1 |
20080183259 | Bly | Jul 2008 | A1 |
20080183264 | Bly | Jul 2008 | A1 |
20080234779 | Pedersen | Sep 2008 | A1 |
20080288017 | Kieval | Nov 2008 | A1 |
20080312712 | Penner | Dec 2008 | A1 |
20090005859 | Keilman | Jan 2009 | A1 |
20090036940 | Wei | Feb 2009 | A1 |
20090155336 | Rezai | Jun 2009 | A1 |
20090171411 | Machado | Jul 2009 | A1 |
20090228078 | Zhang | Sep 2009 | A1 |
20090248119 | Libbus | Oct 2009 | A1 |
20090275997 | Faltys | Nov 2009 | A1 |
20090276025 | Burnes | Nov 2009 | A1 |
20090318989 | Tomaschko | Dec 2009 | A1 |
20100036451 | Hoffer | Feb 2010 | A1 |
20100100151 | Terry, Jr. | Apr 2010 | A1 |
20100113890 | Cho | May 2010 | A1 |
20100114254 | Kornet | May 2010 | A1 |
20100137949 | Mazgalev | Jun 2010 | A1 |
20100191304 | Scott | Jul 2010 | A1 |
20100204741 | Tweden | Aug 2010 | A1 |
20100222832 | Zhang | Sep 2010 | A1 |
20110029037 | Rezai | Feb 2011 | A1 |
20110098762 | Rezai | Apr 2011 | A1 |
20110152877 | Bly | Jun 2011 | A1 |
20110152974 | Rezai | Jun 2011 | A1 |
Number | Date | Country |
---|---|---|
WO 2005065771 | Jul 2005 | WO |
WO 2007075593 | Jul 2007 | WO |
WO2007092330 | Aug 2007 | WO |
WO 2008070189 | Jun 2008 | WO |
W02008092246 | Aug 2008 | WO |
WO 2009075750 | Jun 2009 | WO |
WO 2010017457 | Feb 2010 | WO |
WO2013022543 | Feb 2013 | WO |
Entry |
---|
Bilgutay et al, Vagal Tuning: a new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure, Journal of Thoracic of Cardiovascular Surgery, 1968, vol. 56, No. 1, 71-82. |
Cooper et al, Neural effects on sinus rate and atrioventricular conduction produced by electrical stimulation from a transvenous electrode catheter in the canine right pulmonary artery, Circ. Res. 1980; 46; 48-57. |
Koizumi et al, Function significance of coactivation of vagal and sympathetic cardiac nerves, Proc. Natl. Acad. Sci., USA, (1982)79: 2116-2120. |
Bernston et al, Autonomic Determinism: The Modes of Autonomic Control, the Doctrine of Autonomic Space, and the Laws of Autonomic Constraint, Psychological Review, 1991, vol. 98, No. 4, 459-487. |
Carlson et al, Selective Stimulation of Parasympathetic Nerve Fibers to the Human SA Node, Circulation, 1992: 85: 1311-1317. |
Yang et al, Sequence of excitation as a factor in sympathetic-parasympathetic interactions in the heart, Circ. Res., 1992, 71: 898-905. |
Thompson, Bradycardia Induced by Intravascular Versus Direct Stimulation of the Vagus Nerve, Ann Thorac. Surg, 1998, 65: 637-42. |
Schuarte et al, Ventricular Rate Control During Atrial Fibrillation by Cardiac Parasympathetic Nerve Stimulation: A Transvenous Approach, Journal of the American College of Cardiology, vol. 34, No. 7 (Dec. 1999) p. 2043-50. |
Schuarte et al, Catheter Stimulation of Cardiac Parasympathetic Nerves in Humans: A Novel Approach to the Cardiac ANS, Circulation 2001, 104: 2430-2435. |
Kawashima et al, The autonomic nervous system of the human heart with special reference to its origin, course, and peripheral distribution, Anat Embryol, 2005, 209: 425-438. |
Paton et al, The yin and yang of cardiac autonomic control: Vago-sympathetic interactions revisited, Brain Research Reviews, 2005, 49(3): 555-65. |
Berntson et al, Cardiac autonomic balance versus cardiac regulatory capacity, Psychophysiology, 2008, 45: 643-652. |
Olshansky, et al, Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Implications for Therapy, Circulation 2008, 118: 863-871. |
Meyer et al, Augmentation of Left Ventricular Contractility by Cardiac Sympathetic Neural Stimulation, Circ. Res., 2010, 121: 1286-1294. |
Brown et al, Long term bradycardia by electrical pacing: a new method for studying heart rate reduction, Cardiovascular Research, 1994; 28: 1774-1779. |
Goldberger et al, New technique for vagal nerve stimulation, Journal of Neuroscience Methods 91 (1999), 109-114. |
Li et al, Vagal Nerve Stimulation Markedly Improves Long-Term Survival After Chronic Heart Failure in Rats, Circulation 2004; 109-120-124. |
Schwartz et al, Long term vagal stimulation in patients with advanced heart failure. First experience in man., European Journal of Heart Failure 10(2008) 884-891. |
Nabutovsky et al, Lead Design and Initial Applications of a New Lead for Long-Term Endovascular Vagal Stimulation, PACE, vol. 30, S215-S218. 2007. |
Extended European Search Report for EP12777812.4, which corresponds to the present application. |
PCT Search Report for PCT/US12/035712, which corresponds to the present application. |
PCT Search Report for PCT/US12/046332. |
File History for Related U.S. Appl. No. 13/547,035. |
File History for Related U.S. Appl. No. 14/151,755. |
File History for Related U.S. Appl. No. 13/547,031. |
File History for Related U.S. Appl. No. 14/516,734. |
PCT Search Report for PCT/US2012/046329. |
Supplementary European Search Report for European Application No. 12821988.8, corresponding to PCT/US2012/046332. |
Janes et al, Anatomy of Human Extrinsic Cardiac Nerves and Ganglia, Am. J. Cardiol 57: 299-309, 1986. |
Number | Date | Country | |
---|---|---|---|
20140052208 A1 | Feb 2014 | US |
Number | Date | Country | |
---|---|---|---|
61480305 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2012/035712 | Apr 2012 | US |
Child | 14064544 | US |